These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19086647)

  • 1. [Quantitative approach for calculation of pharmacodynamic interactions and simulation of combined response].
    Chen JC; Pan YJ; Li XS; Sun J; Liu HX; Sun RY; Zheng QS
    Zhongguo Zhong Yao Za Zhi; 2008 Aug; 33(16):2029-33. PubMed ID: 19086647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.
    Jonker DM; Visser SA; van der Graaf PH; Voskuyl RA; Danhof M
    Pharmacol Ther; 2005 Apr; 106(1):1-18. PubMed ID: 15781119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and simulation in molecular pharmacology.
    Mihalas GI; Kygyosi A; Lungeanu D; Vernic C
    Stud Health Technol Inform; 1998; 52 Pt 1():372-5. PubMed ID: 10384481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents.
    Sühnel J
    Arzneimittelforschung; 1992 Oct; 42(10):1251-8. PubMed ID: 1472147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative design of drug compatibility by weighted modification method.
    Zheng QS; Sun RY
    Zhongguo Yao Li Xue Bao; 1999 Nov; 20(11):1043-51. PubMed ID: 11270973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hill equation: a review of its capabilities in pharmacological modelling.
    Goutelle S; Maurin M; Rougier F; Barbaut X; Bourguignon L; Ducher M; Maire P
    Fundam Clin Pharmacol; 2008 Dec; 22(6):633-48. PubMed ID: 19049668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The methodology for researching the combined action of pharmacological substances by using the mathematical theory of experiments].
    Vladimirov VG; Smirnova SM; Boĭko VN
    Eksp Klin Farmakol; 1993; 56(6):59-62. PubMed ID: 8111303
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacodynamic interaction model and its clinical application].
    Tang M; Zhang W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Jun; 26(3):692-6. PubMed ID: 19634700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose addition and the isobole method as approaches for predicting the cumulative effect of non-interacting chemicals: a critical evaluation.
    Bosgra S; van Eijkeren JC; Slob W
    Crit Rev Toxicol; 2009; 39(5):418-26. PubMed ID: 19514914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical factors in studying drug interactions.
    Adler MW
    NIDA Res Monogr; 1986; 68():6-14. PubMed ID: 3095656
    [No Abstract]   [Full Text] [Related]  

  • 13. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of pharmacological experiments using unbiased models of agonist-antagonist interaction.
    Vere DW
    J Pharmacol Exp Ther; 1978 Jun; 205(3):617-23. PubMed ID: 660533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies with two investigational interventions: a simple model to assess their effects and interaction.
    de Mey C; Sparrow P
    Int J Clin Pharmacol Res; 1989; 9(5):297-303. PubMed ID: 2625369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ways of increasing the reliability of assessments of combined action].
    Tiul'menkov VV
    Gig Sanit; 1991 Feb; (2):89-90. PubMed ID: 2055532
    [No Abstract]   [Full Text] [Related]  

  • 17. Patterns and causes of species richness: a general simulation model for macroecology.
    Gotelli NJ; Anderson MJ; Arita HT; Chao A; Colwell RK; Connolly SR; Currie DJ; Dunn RR; Graves GR; Green JL; Grytnes JA; Jiang YH; Jetz W; Kathleen Lyons S; McCain CM; Magurran AE; Rahbek C; Rangel TF; Soberón J; Webb CO; Willig MR
    Ecol Lett; 2009 Sep; 12(9):873-86. PubMed ID: 19702748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovering plausible mechanistic details of hepatic drug interactions.
    Lam TN; Hunt CA
    Drug Metab Dispos; 2009 Jan; 37(1):237-46. PubMed ID: 18936110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on fingerprints correlated with pharmacodynamic of Paeonia lacliflora and Glycyrrhiza uralensis effective compounds].
    Shen L; Zhang L; Feng Y; Xu DS; Lin X
    Zhongguo Zhong Yao Za Zhi; 2008 Nov; 33(22):2658-62. PubMed ID: 19216166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches.
    Musmuca I; Simeoni S; Caroli A; Ragno R
    J Chem Inf Model; 2009 Jul; 49(7):1777-86. PubMed ID: 19499914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.